

Other indications for Basiliximab

- *Acute graft-versus-host disease (aGVHD), refractory treatment (off-label use):* IV: 20 mg on days 1 and 4; may repeat for recurrent acute GVHD. ^[1]

[1] - Schmidt-Hieber M, Feitz T, Knauf W, et al, "Efficacy of the Interleukin-2 Receptor Antagonist Basiliximab in Steroid-Refractory Acute Graft-Versus-Host Disease, Br J Haematol, 2005, 130(4):568-74. [\[PubMed 16098072\]](#)

